Basis of Presentation and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2016

Basis of Presentation and Summary of Significant Accounting Policies

Schedule of customers representing 10% or more of revenues

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
AmerisourceBergen Drug Corporation	22	%	19	%	23	%	24	%
Caremark LLC (Specialty Pharmacy)	10	%	<10	%	10	%	<10	%
McKesson Corporation	<10	%	<10	%	<10	%	10	%
Takeda Pharmaceuticals Company Limited	—	%	32	%	—	%	24	%

Schedule of customers representing greater than 10% of accounts receivable balances

	June 30, 2016		December 31, 2015
AmerisourceBergen Drug Corporation	13	%	43	%
Caremark LLC (Specialty Pharmacy)	11	%	<10	%

Analysis of U.S. product sales allowances and accruals

Our U.S. product sales, which primarily represented revenues from Makena and Feraheme for the three and six months ended June 30, 2016 and 2015, were offset by provisions for allowances and accruals as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Gross U.S. product sales	$	176,581	$	136,589	$	328,773	$	262,106
Provision for U.S. product sales allowances and accruals:
Contractual adjustments		53,938		39,251		99,519		74,385
Governmental rebates		19,660		12,686		36,707		25,654
Total provision for U.S. product sales allowances and accruals		73,598		51,937		136,226		100,039
U.S. product sales, net	$	102,983	$	84,652	$	192,547	$	162,067